Introduction and Background
===========================

Retinal vein occlusions (RVO) are the second most frequent major retinal vascular disease after diabetic retinopathy.[@b1-oed-4-2012-015] The affected vein can be the central retinal vein (central retinal vein occlusion, CRVO) ([Fig. 1](#f1-oed-4-2012-015){ref-type="fig"}), or more commonly one of its retinal branches (branch retinal vein occlusion, BRVO), mainly the superior temporal BRVO ([Fig. 2](#f2-oed-4-2012-015){ref-type="fig"}).[@b2-oed-4-2012-015] Venous thrombus formation leads to poor venous drainage, dilation and tortuosity of the large retinal veins, and increased retinal capillary pressure. These changes result ultimately in exudation of blood, fluid, and lipid into the retina, leading to the development of macular edema (ME).[@b3-oed-4-2012-015] ME is the leading cause of visual impairment in patients with RVO.[@b4-oed-4-2012-015]

Macular grid laser photocoagulation has been considered the gold standard therapy for ME due to RVO through the last three decades. The photocoagulation of the photoreceptors reduces the oxygen consumption of the outer retina and allows oxygen to diffuse from the choroid to the inner retina, where it relieves hypoxia.[@b5-oed-4-2012-015]--[@b7-oed-4-2012-015] Clinical trials demonstrated a moderate efficacy of macular photocoagulation in eyes with branch BRVO,[@b8-oed-4-2012-015] but not in cases with central CRVO.[@b9-oed-4-2012-015]

The SCORE trial (Standard Care versus Corticosteroid for Retinal Vein Occlusion) was a phase III multicenter clinical trial that compared standard care versus 1 or 4 mg preservative-free intravitreal triamcinolone (IVTA) for ME due to CRVO and BRVO. In CRVO patients, IVTA was superior to observation, and the 1 mg dose had a better safety profile. In BRVO patients IVTA was not superior to grid photocoagulation and was linked to high negative side effects.[@b10-oed-4-2012-015]

More recently, a sustained delivery biodegradable dexamethasone implant (DEX implant; Ozurdex; Allergan, Inc., Irvine, CA) has been shown to be an effective therapy for ME due to RVO. However, over 12 months, significant cataract progression occurred in 29.8% of phakic patients receiving a second DEX implant. On the other hand, only 15.4% of patients developed a significant intraocular pressure increase, which otherwise was transient and controlled with either topical medication or observation.[@b11-oed-4-2012-015] This means that, with regard to triamcinolone, the new dexamethasone intravitreal implant improves relatively the safety profile when considering IOP raise, but there is still a safety concern with cataract progression after the second and further retreatments. Perhaps the only clear indication for the intravitreal DEX implant may be pseudophakic vitrectomized patients.

The huge improvement of visual outcomes achieved by repeated intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) in macular edema due to RVO has changed the therapeutic perspective of this entity. The purpose of the present manuscript is to review the major efficacy and safety concerns of the treatment of macular edema in RVO with ranibizumab.

Rationale for the Use of Antiangiogenic Agents in the Management of Macular Edema due to Retinal Vein Occlusion
===============================================================================================================

Following RVO, functional and structural changes in the retinal capillaries, in addition to reduced retinal blood flow, lead to the development of hypoxia. These changes trigger upregulation and intraocular release of several inflammatory factors (mainly interleukin 6 and 8, monokine induced by interferon γ, monocyte chemotactic protein 1, inducible protein 10), and especially a key mediator: vascular endothelial growth factor (VEGF). High levels of VEGF-A have been detected in the ocular fluids of patients with RVO.[@b12-oed-4-2012-015]--[@b14-oed-4-2012-015]

VEGF is a disulfide linked homodimer composed of two 23-kDa subunits. VEGF plays a key role in the pathogenesis of ME secondary to retinal vascular diseases as far as it increases the vascular permeability,[@b15-oed-4-2012-015] and promotes inflammation.[@b16-oed-4-2012-015] Thus, inhibition of VEGF is reasonable and clearly justified when managing ME due to RVO.

Until the approval of ranibizumab for ME due to RVO, intravitreal bevacizumab (Avastin; Genentech, San Francisco, CA) has been widely used for this indication in an off-label fashion, and with a lack of randomized clinical trials ensuring its systemic safety profile. Anyway, we must remember that ranibizumab and bevacizumab are different molecules,[@b17-oed-4-2012-015] and a key difference between them is the systemic effect of bevacizumab, which induces a significant reduction in VEGF plasma levels following a single intravitreal injection.[@b18-oed-4-2012-015],[@b19-oed-4-2012-015]

There is still controversy over the potential role of ranibizumab in cases with ischemic forms of RVO. While some preclinical studies have hypothesized a harmful effect of this treatment in cases with retinal ischemia, others conclude that there is no increase in the avascular area of the ischemic retina. In our experience, cases with ischemic BRVO and CRVO evidenced an analogous anatomical response in comparison to cases with perfused RVO. Obviously, the visual outcome may be limited to the associated ischemic damage in such cases.

Ranibizumab for Macular Edema due to Retinal Vein Occlusion: Summary of Clinical Evidences
==========================================================================================

The terms "retinal vein occlusion" and "ranibizumab" retrieved 51 publications in Pub Med. However, an electronic search limited to "clinical trials" was performed in order to review those manuscripts offering the first level of evidence for the present review. All available data from the selected articles were extracted and tabulated with respect to each study's identity, its design (prospective or retrospective, randomized or not randomized), protocol treatment, time of follow-up, baseline and final visual acuity, baseline and final central subfield thickness, mean number of intravitreal injection, number of ocular adverse events, number of systemic adverse events.

Twelve clinical trials focusing in ranibizumab for ME due to RVO have been reported.[@b3-oed-4-2012-015],[@b20-oed-4-2012-015]--[@b30-oed-4-2012-015] Overall, the clear conclusion of them is that *ranibizumab is an effective and safe* therapeutic approach. The main results are summarized in [Table 1](#t1-oed-4-2012-015){ref-type="table"}.

In those trials reporting results after 24-month follow-up,[@b3-oed-4-2012-015],[@b24-oed-4-2012-015]--[@b27-oed-4-2012-015] the mean visual acuity improved in +15.3 letters ([Table 1](#t1-oed-4-2012-015){ref-type="table"}). Such an impressive visual outcome is achieved both in fixed monthly injections protocols and also in *pro re nata* retreatment protocols. However, no comparative study between these two regimens has yet been published. Initially, after a single injection of ranibizumab, there is a rapid increase in visual acuity parallel to a significant decrease in the retinal thickness as measured by optical coherence tomography. Further retreatments achieve small visual gains after this initial one, but contribute to stabilize the ME and the visual acuity.

The proportion of local or systemic adverse events related to the treatment with ranibizumab varies from 0,009 to 0,11. These data evidences the safety of ranibizumab even in cases with associated cardiovascular systemic risk factors, which is the case of patients with RVO ([Table 2](#t2-oed-4-2012-015){ref-type="table"}).

Although no definite recommendation may be delivered with the actual data available, the classical initial management of waiting at least three months to treat patients with ME due to RVO seems to be clearly obsolete due to the results from these trials.

Conclusion
==========

Nowadays, ranibizumab is the most efficient and safe therapy in the management of ME secondary to both BRVO and CRVO. The intravitreal injection of 0.5 mg of ranibizumab in these cases leads to a rapid decrease of the macular thickness and to significant improvements in visual acuity.

It is important to underline that this review focus on ranibizumab, and the results provided by this treatment must not be extrapolated to *bevacizumab*. These are two different molecules[@b17-oed-4-2012-015] which share the inhibition of VEGF-A as their main mechanism of action; but bevacizumab has not proven its safety in randomized clinical trials, whereas ranibizumab has evidenced an excellent safety profile in several trials of patients with RVO.

Further studies are warranted in order to provide the guidelines that may enable the retinal physicians to optimize the visual outcomes in cases of ME due to RVO, and to establish retreatment protocols looking for less number of injections and visits to the hospital. Until then, we can clearly state that the standard of care for these patients is the intravitreal injection of ranibizumab.
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![Brach retinal vein occlusion. (**A1**) Retinography showing superior temporal branch retinal vein occlusion in a 72-year-old female complaining for blurred vision for the last three weeks. Retinal hemorrhages are located in the superior temporal retinal quadrant with macular involvement; (**A2**) Horizontal foveal-centerred optical coherence tomography scan showing the presence of diffuse retinal thickening, with small cystic intraretinal spaces, and neurosensory foveal detachment. (**B1**) Retinography after two monthly intravitreal injections of ranibizumab. The visual acuity improved from 20/60 at baseline to 20/20. Important regression of the retinal hemorrhages can be appreciated; (**B2**) Complete resolution of the macular edema as evidenced in the optical coherence tomography.](oed-4-2012-015f1){#f1-oed-4-2012-015}

![Central retinal vein occlusion. (**A1**) Retinography showing central retinal vein occlusion in a 42-year-old male complaining for blurred vision for the last five days. Retinal hemorrhages can be appreciated in all the four retinal quadrants; (**A2**) Horizontal foveal-centerred optical coherence tomography scan showing the presence of diffuse retinal cystoid macular edema, and neurosensory foveal detachment. (**B1**) Retinography after twelve-month follow-up and four intravitreal injections of ranibizumab combined with panretinal photocoagulation. The visual acuity improved from 20/200 at baseline to 20/25; (**B2**) Complete resolution of the macular edema as evidenced in the optical coherence tomography. A secondary epimacular membrane can be seen as an hyperreflective lineal structure overlying the internal limiting membrane in the nasal side.](oed-4-2012-015f2){#f2-oed-4-2012-015}

###### 

Summary of the main ocular changes in vision and central subfield thickness in the main clinical trials.

  **Reference number**   **Type of retinal vein occlusion**                      **Follow-up**   **Treated eyes**   **Injections**   **Baseline visual acuity**   **Average visual gain**   **Baseline CST**   **Average change CST**   **Injections per patient**   **Ocular adverse event per patient**   **Ocular adverse event per injection**   **Systemic adverse event per patient**   **Systemic adverse event per injection**
  ---------------------- ------------------------------------------------------- --------------- ------------------ ---------------- ---------------------------- ------------------------- ------------------ ------------------------ ---------------------------- -------------------------------------- ---------------------------------------- ---------------------------------------- ------------------------------------------
  3                      CRVO                                                    24              10                 ND               ND                           1                         ND                 119                      4,5                          0                                      0                                        0                                        0
  20                     CRVO                                                    3               10                 20               23                           14                        297                35                       2                            0                                      0                                        0                                        0
  20                     BRVO                                                    3               10                 20               20                           18                        288                51                       2                            0                                      0                                        0                                        0
  21                     CRVO                                                    12              20                 170              45,8                         64,3                      574,6              186                      8,5                          0                                      0                                        0,05                                     0,006
  22                     CRVO                                                    6               129                774              48,1                         14,9                      688,7              452                      6                            0,09                                   0,02                                     0,02                                     0,004
  23                     BRVO                                                    6               130                780              53                           18,3                      551,7              345                      6                            0,05                                   0,009                                    0,04                                     0,006
  24                     CRVO                                                    24              35                 526              44,2                         17,8                      638                164                      6,6                          0,11                                   0,007                                    0,03                                     0,002
  25                     CRVO                                                    24              15                 64               45                           12                        625                304                      4,3                          0,2                                    0,04                                     ND                                       ND
  26                     CRVO                                                    24              14                 ND               ND                           8,5                       ND                 337,7                    3,5                          ND                                     ND                                       ND                                       ND
  26                     BRVO                                                    24              17                 ND               ND                           17,8                      ND                 245,8                    2                            ND                                     ND                                       ND                                       ND
  27                     CRVO[\*](#tfn2-oed-4-2012-015){ref-type="table-fn"}     24              10                 ND               56,6                         10                        616,2              304                      ND                           0                                      0                                        0,1                                      ND
  27                     CRVO[\*\*](#tfn3-oed-4-2012-015){ref-type="table-fn"}   24              10                 ND               46,5                         3,7                       604,8              282                      ND                                                                                                                                                    
  29                     BRVO                                                    12              ND                 ND               53                           18,3                      551                374,4                    ND                           0,07                                   ND                                       0,05                                     ND
  30                     CRVO                                                    12              ND                 ND               48,1                         13,9                      688,7              472,2                    ND                           0,13                                   ND                                       0,03                                     ND

**Notes:**

Pro re nata monthly follow-up;

Pro re nata as needed.

**Abbreviation:** ND, Non described.

###### 

Summary of ocular and nonocular adverse events in the main clinical trials.

                                                                    **References**   **Total**                                           
  ----------------------------------------------------------------- ---------------- ----------- ---- ---- ---- ---- ---- ---- ---- ---- ----
  **Eye adverse events**                                                                                                                 
  Any intraocular inflammation (iridocyclitis, iritis, vitritis)    ND               ND          2    ND   ND   ND   ND   ND   ND   2    2
  Endophthalmitis                                                   ND               ND          ND   1    ND   ND   ND   ND   1    ND   2
  Lens damage                                                       ND               ND          ND   ND   ND   ND   ND   ND   ND   ND   0
  Cataract                                                          ND               ND          2    4    3    ND   ND   ND   8    9    24
  Iris neovscularization                                            ND               ND          1    ND   ND   ND   ND   ND   1    5    6
  Neovascular glaucoma                                              ND               ND          ND   ND   1    ND   ND   ND   ND   1    2
  Rhegmathofenous retinal detachment                                ND               ND          ND   ND   ND   ND   ND   ND   ND   ND   0
  Retinal tear                                                      ND               ND          ND   ND   ND   1    ND   ND   ND   2    3
  Vitreous hemorrhage                                               ND               ND          7    2    ND   ND   ND   ND   1    1    4
  Retinal vein trombosis                                            ND               ND          ND   ND   ND   1    ND   ND   ND   ND   1
  **Nonocular serious adverse events-related to VEGF inhibition**                                                                        
  Hemorrhagic stroke                                                ND               ND          ND   1    ND   ND   ND   1    1    ND   3
  Ischemic attack                                                   ND               ND          ND   ND   1    ND   ND   ND   ND   1    2
  Transient ischemic attack                                         ND               ND          1    ND   1    ND   ND   ND   ND   1    2
  Myocardial infarction                                             ND               ND          1    1    ND   ND   ND   1    1    1    4
  Angina pector                                                     ND               ND          1    1    ND   ND   ND   ND   1    1    3
  Hypertension                                                      ND               ND          ND   ND   ND   ND   ND   ND   1    ND   1
  Nonocular hemorrhage                                              ND               ND          ND   1    ND   ND   ND   ND   1    ND   2
  Intestinal perforation                                            ND               ND          ND   1    ND   ND   ND   ND   1    ND   2
  Proteinuria                                                       ND               ND          ND   ND   ND   ND   ND   ND   ND   ND   0

**Note:** The line on the top shows the reference corresponding to each clinical trial corresponding to the references listed.

**Abbreviation:** ND, None described.
